Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018668 · ClinicalTrials.gov registry record · Phase 4
Antipsychotic Response in Schizophrenia
A Phase 4 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00018668: Completed Phase 4 study, sponsored by US Department of Veterans Affairs.
NCT00018668 is a Phase 4 study that has completed, run by US Department of Veterans Affairs. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018668, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for distinguishing subtypes of motor slowing - one type related to cognitive processes and another related to parkinsonism. The purpose of this study is to test whether new medications used to treat schizophrenia improve the cognitive or parkinsonian components of motor slowing. Patients will be studied in the laboratory before and 8-weeks after starting a new antipsychotic. The n of this study = 60 patients. The results of this study will improve our understanding of the complex interactions between cognitive processing and motor behavior in patients with psychotic illnesses and how drugs work to treat these problems.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
What the finished NCT00018668 record still lists
NCT00018668 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT00018668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00018668 about?
NCT00018668 is a clinical study titled "Antipsychotic Response in Schizophrenia". Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for d...
What is the current status of trial NCT00018668?
This trial is currently completed. It is a Phase 4 study. The study started on 2000-10. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00018668?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00018668?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia